Concurrent estimation of lamivudine, tenofovir disoproxil fumarate, and efavirenz in blended mixture and triple combination tablet formulation by a new stability indicating RP-HPLC method
Abstract Background An easy, defined, rapid, and accurate reverse phase high-performance liquid chromatography method was developed and subsequently validated for the concurrent estimation of lamivudine, efavirenz, and tenofovir disoproxil fumarate in their pure blend and combined tablet formulation...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
SpringerOpen
2021-04-01
|
Series: | Future Journal of Pharmaceutical Sciences |
Subjects: | |
Online Access: | https://doi.org/10.1186/s43094-021-00249-9 |
id |
doaj-1ed32321eefa4a5eb823c9b93a5d6c08 |
---|---|
record_format |
Article |
spelling |
doaj-1ed32321eefa4a5eb823c9b93a5d6c082021-05-02T11:44:15ZengSpringerOpenFuture Journal of Pharmaceutical Sciences2314-72532021-04-017111210.1186/s43094-021-00249-9Concurrent estimation of lamivudine, tenofovir disoproxil fumarate, and efavirenz in blended mixture and triple combination tablet formulation by a new stability indicating RP-HPLC methodRamreddy Godela0Vijayalaxmi Kammari1Sowjanya Gummadi2Durgaprasad Beda3Department of Pharmacy, GITAM Deemed to be UniversityDepartment of Pharmaceutical Analysis, MLR Institute of PharmacyDepartment of Pharmacy, GITAM Deemed to be UniversityDepartment of Pharmaceutical Analysis, Bhaskar Pharmacy CollegeAbstract Background An easy, defined, rapid, and accurate reverse phase high-performance liquid chromatography method was developed and subsequently validated for the concurrent estimation of lamivudine, efavirenz, and tenofovir disoproxil fumarate in their pure blend and combined tablet formulation. An efficient and appropriate separation of the three analytes was attained with Zorbax eclipse XDB-Phenyl column, with a mobile phase of methanol: buffer (0.1% v/v formic acid in water) (73:27 v/v) at a flow rate of 1mL/min and isocratic elution by using 260nm as detection wavelength. Equal ratio of acetonitrile and water was used as diluent. Results The retention times of lamivudine, tenofovir disoproxil fumarate, and efavirenz were found at 2.6, 4.4, and 5.9 min respectively. The linear response for lamivudine, tenofovir disoproxil fumarate, and efavirenz was in the range of 15.0–45.0μg/mL, 15.0–45.0μg/mL, and 20.0–60.0 μg/mL respectively. The method validation was done in accordance to ICH guidelines and all validation parameters in compliance with ICH standards. The degradants produced by stress testing were well resolved from the peaks of active analytes, which stipulates the stability-indicating property of the method. Conclusion The method has the ability to separate lamivudine, efavirenz, and tenofovir disoproxil fumarate concurrently in blended powder and their combined tablet. All degradants produced by application of stress conditions were separated with high resolution and determined with good sensitivity that ensures the stability-indicating property of the method. Thus, the projected method has high probability to adopt in the pharmaceutical industrial sector.https://doi.org/10.1186/s43094-021-00249-9LamivudineEfavirenzTenofovir disoproxil fumarateStress testingStability indicatingIsocratic elution |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Ramreddy Godela Vijayalaxmi Kammari Sowjanya Gummadi Durgaprasad Beda |
spellingShingle |
Ramreddy Godela Vijayalaxmi Kammari Sowjanya Gummadi Durgaprasad Beda Concurrent estimation of lamivudine, tenofovir disoproxil fumarate, and efavirenz in blended mixture and triple combination tablet formulation by a new stability indicating RP-HPLC method Future Journal of Pharmaceutical Sciences Lamivudine Efavirenz Tenofovir disoproxil fumarate Stress testing Stability indicating Isocratic elution |
author_facet |
Ramreddy Godela Vijayalaxmi Kammari Sowjanya Gummadi Durgaprasad Beda |
author_sort |
Ramreddy Godela |
title |
Concurrent estimation of lamivudine, tenofovir disoproxil fumarate, and efavirenz in blended mixture and triple combination tablet formulation by a new stability indicating RP-HPLC method |
title_short |
Concurrent estimation of lamivudine, tenofovir disoproxil fumarate, and efavirenz in blended mixture and triple combination tablet formulation by a new stability indicating RP-HPLC method |
title_full |
Concurrent estimation of lamivudine, tenofovir disoproxil fumarate, and efavirenz in blended mixture and triple combination tablet formulation by a new stability indicating RP-HPLC method |
title_fullStr |
Concurrent estimation of lamivudine, tenofovir disoproxil fumarate, and efavirenz in blended mixture and triple combination tablet formulation by a new stability indicating RP-HPLC method |
title_full_unstemmed |
Concurrent estimation of lamivudine, tenofovir disoproxil fumarate, and efavirenz in blended mixture and triple combination tablet formulation by a new stability indicating RP-HPLC method |
title_sort |
concurrent estimation of lamivudine, tenofovir disoproxil fumarate, and efavirenz in blended mixture and triple combination tablet formulation by a new stability indicating rp-hplc method |
publisher |
SpringerOpen |
series |
Future Journal of Pharmaceutical Sciences |
issn |
2314-7253 |
publishDate |
2021-04-01 |
description |
Abstract Background An easy, defined, rapid, and accurate reverse phase high-performance liquid chromatography method was developed and subsequently validated for the concurrent estimation of lamivudine, efavirenz, and tenofovir disoproxil fumarate in their pure blend and combined tablet formulation. An efficient and appropriate separation of the three analytes was attained with Zorbax eclipse XDB-Phenyl column, with a mobile phase of methanol: buffer (0.1% v/v formic acid in water) (73:27 v/v) at a flow rate of 1mL/min and isocratic elution by using 260nm as detection wavelength. Equal ratio of acetonitrile and water was used as diluent. Results The retention times of lamivudine, tenofovir disoproxil fumarate, and efavirenz were found at 2.6, 4.4, and 5.9 min respectively. The linear response for lamivudine, tenofovir disoproxil fumarate, and efavirenz was in the range of 15.0–45.0μg/mL, 15.0–45.0μg/mL, and 20.0–60.0 μg/mL respectively. The method validation was done in accordance to ICH guidelines and all validation parameters in compliance with ICH standards. The degradants produced by stress testing were well resolved from the peaks of active analytes, which stipulates the stability-indicating property of the method. Conclusion The method has the ability to separate lamivudine, efavirenz, and tenofovir disoproxil fumarate concurrently in blended powder and their combined tablet. All degradants produced by application of stress conditions were separated with high resolution and determined with good sensitivity that ensures the stability-indicating property of the method. Thus, the projected method has high probability to adopt in the pharmaceutical industrial sector. |
topic |
Lamivudine Efavirenz Tenofovir disoproxil fumarate Stress testing Stability indicating Isocratic elution |
url |
https://doi.org/10.1186/s43094-021-00249-9 |
work_keys_str_mv |
AT ramreddygodela concurrentestimationoflamivudinetenofovirdisoproxilfumarateandefavirenzinblendedmixtureandtriplecombinationtabletformulationbyanewstabilityindicatingrphplcmethod AT vijayalaxmikammari concurrentestimationoflamivudinetenofovirdisoproxilfumarateandefavirenzinblendedmixtureandtriplecombinationtabletformulationbyanewstabilityindicatingrphplcmethod AT sowjanyagummadi concurrentestimationoflamivudinetenofovirdisoproxilfumarateandefavirenzinblendedmixtureandtriplecombinationtabletformulationbyanewstabilityindicatingrphplcmethod AT durgaprasadbeda concurrentestimationoflamivudinetenofovirdisoproxilfumarateandefavirenzinblendedmixtureandtriplecombinationtabletformulationbyanewstabilityindicatingrphplcmethod |
_version_ |
1721491705480347648 |